H.C. Wainwright lowered the firm’s price target on Kyverna Therapeutics (KYTX) to $4 from $6 and keeps a Neutral rating on the shares following the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics price target lowered to $20 from $40 at Morgan Stanley
- Kyverna Therapeutics: Strategic Advancements and Robust Financial Health Underpin Buy Rating
- Kyverna Therapeutics price target lowered to $12 from $13 at UBS
- Kyverna Therapeutics Advances CAR T-Cell Therapy Trials
- Kyverna Therapeutics files $250M mixed securities shelf